Impact of blood transfusion on survival after nephrectomy for localized or locally advanced renal cancer.


Journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 19 10 2021
revised: 20 02 2022
accepted: 08 03 2022
pubmed: 7 5 2022
medline: 22 6 2022
entrez: 6 5 2022
Statut: ppublish

Résumé

Several studies have reported blood transfusion were associated with a decrease of survival after oncological surgery. For kidney cancer, the effect of blood transfusion is still debated. The objective of this study was to determine the effect of blood transfusion after oncological nephrectomy on overall, specific and recurrence-free survival in a retrospective cohort of localized or locally advanced kidney cancer. We performed a monocentric retrospective analysis of all patients managed by surgery for localized or locally advanced renal cancer between January 2000 and December 2016. We compared overall and specific survival and recurrence-free survival between two groups: patients transfused and not transfused. Demographic, surgical and tumor characteristics were compared. Survival analyses were performed using univariate Cox regression and multivariate Cox proportional regression test. We included 382 patients in this study: 320 (83.8%) were not transfused and 62 (16.2%) were transfused. Transfused patients were significantly older (P=0.001) and had a lower pre-operative hemoglobin level (P=0.008). Operative and oncological characteristics were also different between both groups. In univariate analysis, we showed that blood transfusion was associated with lower overall survival (P<0.001), specific survival (P<0.001), and recurrence-free survival (P<0.001). In multivariate analysis, we found that blood transfusion was not associated with overall survival, or specific survival, but it was associated with lower recurrence-free survival (HR: 1.967, CI95% [1.024-3.780], P=0.042). Perioperative blood transfusion is an independent risk factor that increases tumor recurrence among patients treated with nephrectomy for renal cancer.

Identifiants

pubmed: 35523663
pii: S1166-7087(22)00074-4
doi: 10.1016/j.purol.2022.03.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

577-584

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Auteurs

P Détrée (P)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France; University of Franche-Comté, 25000 Besançon, France.

L Balssa (L)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France.

V Richard (V)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France; University of Franche-Comté, 25000 Besançon, France.

C Francois (C)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France; University of Franche-Comté, 25000 Besançon, France.

J Barkatz (J)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France.

S Bernardini (S)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France.

E Chabannes (E)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France.

G Guichard (G)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France.

A Thiery-Vuillemin (A)

University of Franche-Comté, 25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, 25000 Besançon, France; INSERM UMR 1098, 25000 Besançon, France.

F Kleinclauss (F)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France; University of Franche-Comté, 25000 Besançon, France; Nanomedicine Lab, Imagery and Therapeutics". EA 4662, 25000 Besançon, France.

A Frontczak (A)

Department of Urology, Andrology and Renal Transplantation, University Hospital of Besançon, 3, boulevard Fleming, 25000 Besançon, France; University of Franche-Comté, 25000 Besançon, France; Nanomedicine Lab, Imagery and Therapeutics". EA 4662, 25000 Besançon, France. Electronic address: afrontczak@chu-besancon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH